PHARMACYTE BIOTECH, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
PHARMACYTE BIOTECH, INC. (PMCB) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$615 for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-07-31 was -$615.00, a 600.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-07-31 was $123.00, a 32.79% decline year-over-year.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-07-31 was $183.00, a 59.42% decline year-over-year.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-07-31 was $451.00, a 65.41% decline year-over-year.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2026 was $3.07K.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$358.00.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$508.00.
- PHARMACYTE BIOTECH, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$7.25K, a 256.67% decline from fiscal 2022.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$615.00 10-Q · filed 2026-09-14 | |||
| 2026-04-30 | $3.07K 10-K · filed 2026-07-29 | |||
| 2026-01-31 | $2.33K 10-Q · filed 2026-03-17 | |||
| 2025-10-31 | -$258.00 10-Q · filed 2025-12-18 | |||
| 2025-07-31 | $123.00 10-Q · filed 2026-09-14 | |||
| 2025-04-30 | -$358.00 10-K · filed 2026-07-29 | |||
| 2025-01-31 | -$975.00 10-Q · filed 2026-03-17 | |||
| 2024-10-31 | $244.00 10-Q · filed 2025-12-18 | |||
| 2024-07-31 | $183.00 10-Q · filed 2025-09-15 | |||
| 2024-04-30 | -$508.00 10-K · filed 2025-08-11 | |||
| 2024-01-31 | -$70.00 10-Q · filed 2025-03-17 | |||
| 2023-10-31 | -$1.14K 10-Q · filed 2024-12-13 | |||
| 2023-07-31 | $451.00 10-Q · filed 2024-09-17 | |||
| 2023-04-30 | -$7.25K 10-K · filed 2024-08-13 | |||
| 2023-01-31 | -$1.97K 10-Q · filed 2024-03-18 | |||
| 2022-10-31 | $584.00 10-Q · filed 2023-12-15 | |||
| 2022-07-31 | $1.30K 10-Q · filed 2023-09-18 | |||
| 2022-04-30 | $4.63K 10-K · filed 2023-07-31 | |||
| 2022-01-31 | $1.08K 10-Q · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |